Survival Benefits of Statins in Breast Cancer Patients With Abnormal Lipid Metabolism
试验速览
- 阶段
- 3 期
- 入组人数
- 314
- 试验地点
- 1
- 主要终点
- DFS
研究概览
简要总结
In this study, we compared the survival benefit of breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins intervention. The main endpoint was 5 years DFS. The subjects were breast cancer patients.
详细描述
A randomized, open, blank controlled, single-center clinical trial was conducted to compare the survival benefits of statins in breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins. The main endpoint was 3 and 5 years DFS. The subjects were breast cancer patients. In this study, 348 patients were randomly divided into two groups according to patients' wishes and written informed consent. The experimental group: control group = 1:1. Subjects were screened and administered continuously until the disease progressed and the toxicity was intolerable. Informed consent was withdrawn or the researcher decided that the drug must be discontinued.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosed as invasive breast cancer, it has been treated surgically, confirmed by histology, cytology or imaging.
- •Female patients (35-75 years old);
- •The low-risk patients with ASCVD are detailed in Annex
- •Signed written informed consent approved by IRB or IEC
排除标准
- •The subjects were pregnant or lactating.
- •Pregnancy test positive (urine or serum) in women with potential pregnancy within 7 days before administration.
- •Other invasive tumors (including the second primary breast cancer) may affect the evaluation of outcomes and the compliance of schemes, but subjects who have been cured and survived disease-free for at least five years can be selected.
- •Patients with chronic underlying liver diseases who have abnormal liver function and/or clinical manifestations:
- •Serum total bilirubin > 2.5 *ULN; or INR > 1.5 although there was no increase in bilirubin Serum ALT or AST > 3 *ULN; Alkaline phosphatase > 2.5 *ULN; Elevated ALT or AST may gradually recover, but with progressively increased fatigue, nausea and vomiting, fever, right upper abdominal pain or tenderness.
- •Extremely high risk ASCVD patients Including acute coronary syndrome (ACS), stable coronary heart disease, revascularization, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, peripheral atherosclerosis, etc.
- •High-risk ASCVD patients (in accordance with one of the following circumstances):
- •LDL-C>4.9 mmol/L or TC>7.2 mmol/L Diabetic patients with 1.8 mmol/L < LDL-C < 4.9 mmol/L (or) 3.1 mmol/L < TC < 7.2 mmol/L and age < 40 years
- •The 10-year risk of ASCVD was moderate and younger than 55 years old. The remaining life risk was assessed. Those with any of the following two or more risk factors are defined as high risk:
- •Systolic or diastolic blood pressure (> 160 mmHg) or (> 100 mmHg)
- •Non-HDL-C>5.2 mmol/L (200 mg/dl)
- •HDL-C < 1.0 mmol/L (40 mg/dl)
- •BMI>28 kg/m2 Smoking
- •In the abnormal group of simple TG (triglyceride), TG (> 5.7 mmol/L)
- •Other serious diseases, including:
- •Congestive heart failure (NYHA grade II, III, IV); dyspnea at rest or requiring oxygen therapy; severe infection; uncontrolled diabetes mellitus;
- •If there are serious mental or mental disorders, it is estimated that the subjects'compliance to participate in this study is not strong.
- •Drug allergies to research drugs are known.
- •Participated in other drug clinical trials in the past 30 days.
- •Failure to complete at least one cycle of clinical trials based on this protocol, and failure to evaluate safety and effectiveness.
- •Serious violation of this study program, not in accordance with the prescribed dose, method and course of treatment.
研究组 & 干预措施
Statin therapy (experimental group)
On the basis of guiding patients to control their diet and improve their lifestyle, etc.
Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)
干预措施: statins (Drug)
Dietary intervention group (control group)
Guiding patients to control diet, improve lifestyle, etc.
干预措施: Dietary intervention group (control group) (Behavioral)
结局指标
主要结局
DFS
时间窗: 5 years
Disease free survival
次要结局
- OS(5 years)